Polyrizon Ltd., a biotech company focused on intranasal hydrogels, announced significant findings from ex vivo studies that demonstrate the strong mucoadhesion and broad surface coverage of its ...

HIV therapies have come a long way since the 1980s, when the first antiretroviral therapy, AZT, was approved by the FDA. Patients have gone from having to take multiple pills a day to two or even ...

Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today ...

Ra’anana, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a biotechnology company developing intranasal drug delivery systems, today announced ...

Once-a-month long-acting injectable hydrogel could greatly improve management of both type 2 diabetes and weight loss, drug adherence, and long-term health outcomes French researchers have developed a ...

A new hydrogel formulation restores blood flow to diabetic wounds and helps them heal. The corresponding study was published in Burns & Trauma and may allow diabetic wounds to heal in days instead of ...

Several coronavirus disease 2019 (COVID-19) vaccines require multiple doses for long-lasting immunity. However, a new study published in the journal Biomacromolecules has developed a promising ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Pipeline and key clinical candidates for these companies: ...

Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ...